Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Galapagos Appoints David Smith as CEO of Service Division

Published: Wednesday, August 21, 2013
Last Updated: Wednesday, August 21, 2013
Bookmark and Share
David Smith was CFO of Galapagos for two years.

Galapagos NV has announced the appointment of David Smith as CEO of the service division and member of the Galapagos Executive Committee.

Galapagos' service division comprises BioFocus and Argenta. Together with Fidelta, Galapagos has three leaders in premium drug discovery services for pharma, biotech, universities, and patient foundations.

Galapagos' service division and Fidelta meet clients' needs for drug discovery tools and expertise by providing a full range of services, from target discovery through to delivery of pre-clinical candidates, including compound libraries, medicinal chemistry and ADME/PK services.

To further optimize the performance and ensure further growth of this division and Fidelta, a CEO position has been created, to be filled by David Smith.

Chris Newton, John Montana and Phil Dudfield will lead BioFocus, Argenta, and Fidelta, respectively, as Managing Director; they will report to David Smith.

David will become member of the Galapagos Executive Committee and report to Galapagos CEO Onno van de Stolpe.

David Smith joins Galapagos from the Cambridge University Hospitals where he was Director Finance for six years. Previously he was CFO of Galapagos for two years, during which he played a key role in several M&A projects to build the service division between 2005 and 2007.

Prior to that, at AstraZeneca he held Marketing Company CFO roles (where he was also a Board member of the AstraZeneca Dutch Holdings Group) and a number of strategic and integration functions within R&D; at Coopers & Lybrand (now PriceWaterhouseCoopers) he was audit manager to a variety of industries and international clients in Dubai, and post qualification as a Chartered Accountant in Leeds he ran a number of companies in administration. David holds a degree in Molecular Biophysics from the University of Leeds.

"We welcome David back to Galapagos," said Onno van de Stolpe, Chief Executive Officer, Galapagos. "David brings valuable strategic and operational experience to the Galapagos Group, and he is already familiar with the services business from his previous role at the Company. We have confidence that he can take the successful Service division to the next level."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Presents Favorable Phase 1 Data for IBD Target
Galapagos NV discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna.
Tuesday, October 21, 2014
Galapagos Selects Pre-Clinical Candidate for Cystic Fibrosis
Start of Phase 1 expected before end 2014.
Tuesday, December 17, 2013
Galapagos Reports Positive Phase 1 Results for GLPG1205
Company is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.
Wednesday, December 04, 2013
Galapagos Starts Phase Ib Clinical Study in Cancer Patients
Galapagos plans to assess the safety and explore the preliminary efficacy of GLPG0187 in cancer patients.
Tuesday, March 15, 2011
Galapagos Candidate Cachexia Drug, GLPG0492, Shows Good Safety and Profile Suitable for Once-Daily Oral Dosing
Company plans to initiate extended dose and Proof of Concept studies in 2011.
Friday, December 03, 2010
Galapagos Starts Phase II Clinical Trial in Rheumatoid Arthritis Patients
Galapagos NV announced that it has started a Phase II clinical study for the Company’s flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis (RA).
Tuesday, October 19, 2010
Galapagos' Affiliate BioFocus Extends Collaboration with Chiesi
BioFocus to provide medicinal chemistry and biology services, with an additional option for ADME services, for a Chiesi therapeutic program.
Thursday, October 14, 2010
Galapagos Initiates Phase I Study for JAK inhibitor GLPG0634
Company announces the acquisition of full rights to the compound from GSK.
Monday, August 09, 2010
Galapagos and University of Bristol Enter Drug Discovery Collaboration in Chronic Pain
BioFocus will provide hit-to-lead and lead optimization services for a €3.3 million drug discovery program at the University of Bristol.
Friday, July 16, 2010
Galapagos Completes Phase I Clinical Trials for Rheumatoid Arthritis Candidate Drug GLPG0259
Phase II efficacy study in rheumatoid arthritis patients planned to start later this year.
Wednesday, February 24, 2010
Galapagos Delivers Third Candidate Drug in GSK Alliance, Receives €5.7 Million
Galapagos will now start scale-up chemistry and safety evaluation to initiate Phase I clinical trials early 2011.
Tuesday, February 23, 2010
Galapagos Acquires Argenta Discovery's Service Operations
Newly acquired, worth €16.5 million, Argenta unit will operate in parallel to BioFocus.
Friday, February 05, 2010
Galapagos Initiates Nanocort® Phase II Clinical Trial for Multiple Sclerosis
A single administration of Nanocort will be compared to the standard steroid treatment of three methylprednisolone infusions to evaluate Nanocort in treating MS.
Tuesday, November 24, 2009
Galapagos Initiates Second Phase I Clinical Trial for GLPG0259
The new trial is based on the positive outcome of the first-in-human trial conducted earlier in 2009.
Thursday, September 10, 2009
Galapagos Successfully Completes First Phase I Study for GLPG0259
Clinical results demonstrate safety in man Pharmacokinetic profile supports once-daily oral dosing.
Thursday, August 06, 2009
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos